Christy Oliger
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Christy Oliger
Christy Oliger is recorded as Board Member at Bicara Therapeutics Inc. (BCAX). Bicara Therapeutics Inc. reported in an 8-K filed July 28, 2026 that Christy Oliger was appointed member of the Nominating and Corporate Governance Committee, effective July 28, 2026. Bicara Therapeutics Inc. reported in an 8-K filed July 28, 2026 that Christy Oliger was appointed Class II director, effective July 28, 2026.
“Effective as of the Appointment Date, the Board appointed (i) Dr. Bender to serve as a member of the Audit Committee of the Board (the “Audit Committee”), replacing Carolyn Ng, Ph.D., (ii) Ms. Oliger and Dr. Ng to serve as a members of the Nominating and Corporate Governance Committee, replacing Ms. Mazumdar-Shaw and Jake Simson, Ph.D., and (iii) Dr. Bender, Ms. Oliger and Kate Haviland to serve as members of the newly formed Launch Readiness Committee of the Board (the “Launch Readiness Committee”), with Ms. Haviland as chair of the Launch Readiness Committee, each until their respective successors are elected and qualified, or until their earlier death, resignation or removal, or until otherwise determined by the Board.”
“On July 26, 2026, upon the recommendation of the Nominating and Corporate Governance Committee, the Board appointed (i) Jeremy Bender, Ph.D. to serve on the Board as a Class I director to hold office until the Company’s annual meeting of stockholders in 2028 or until his earlier death, resignation or removal, and (ii) Christy Oliger to serve on the Board as a Class II director to hold office until the Company’s annual meeting of stockholders in 2029 or until her earlier death, resignation or removal, with each appointment to be effective as of July 28, 2026 (the “Appointment Date”).”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Bicara Therapeutics Inc. (BCAX)
SEC 8-K
Current2026-07-28–present
-
Current
2026-07-28–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Bicara Therapeutics Inc.
Other people whose current roles at this company are on record from its filings.
- Claire Mazumdar CEO
- Carolyn Ng Board Member
- Christopher Bowden Board Member
- David Raben Board Member
- Ivan Hyep Board Member
- Jeremy Bender, Ph.D. Board Member
- Lara Meisner Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.